KRAS and neoplasm: The in vivo treatment of the KRAS-mutated LLC model with the most representative compound 5i proved that this compound was effective in inducing about 80% reduction in the tumor mass, similar to cisplatin and gemcitabine, but with a body weight loss significantly lower than that induced by reference drugs.